Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation

Journal of Cell Science

Volumn 125, Issue 17, 2012, Pages 4137-4146

  Le Guelte, Armelle ^a,b,c   Galan Moya, Eva Maria ^a,b,c   Dwyer, Julie ^a,b,c   Treps, Lucas ^a,b,c   Kettler, Garance ^a,b,c   Hebda, Jagoda K ^a,b,c   Dubois, Sonia ^d   Auffray, Cedric ^a,b,c   Chneiweiss, Herve ^c,e   Bidere, Nicolas ^d   Gavard, Julie ^a,b,c  

^a CNRS   (France)

^b INSTITUT COCHIN   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSERM U1014   (France)

^e INSERM   (France)

Author keywords

Cell cell junction; Glioma stem cell; Internalisation; Plexin; VE cadherin

Indexed keywords

PHOSPHOPROTEIN PHOSPHATASE 2A; SEMAPHORIN 3A; SMALL INTERFERING RNA; VASCULAR ENDOTHELIAL CADHERIN;

ARTICLE; CELL JUNCTION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; GLIOMA; HUMAN; HUMAN CELL; INTERNALIZATION; MICROVASCULAR ENDOTHELIAL CELL; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION;

ANIMALS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; ENDOTHELIAL CELLS; ENZYME ACTIVATION; GLIOMA; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASTIC STEM CELLS; PROTEIN PHOSPHATASE 2; SEMAPHORIN-3A; SRC-FAMILY KINASES;

EID: 84869138517     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.108282     Document Type: Article

References (53)

1. Acevedo, L. M., Barillas, S., Weis, S. M., Göthert, J. R. and Cheresh, D. A. (2008). Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 111, 2674-2680.
2. Bagci, T., Wu, J. K., Pfannl, R., Ilag, L. L. and Jay, D. G. (2009). Autocrine semaphorin 3A signaling promotes glioblastoma dispersal. Oncogene 28, 3537-3550.
3. Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W. T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P. J., Zhu, M. et al. (2007). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95.
4. Broermann, A., Winderlich, M., Block, H., Frye, M., Rossaint, J., Zarbock, A., Cagna, G., Linnepe, R., Schulte, D., Nottebaum, A. F. et al. (2011). Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGFinduced vascular permeability in vivo. J. Exp. Med. 208, 2393-2401.
5. Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., Oh, E. Y., Gaber, M. W., Finklestein, D., Allen, M. et al. (2007). A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69-82.
6. Carmeliet, P., Lampugnani, M. G., Moons, L., Breviario, F., Compernolle, V., Bono, F., Balconi, G., Spagnuolo, R., Oosthuyse, B., Dewerchin, M. et al. (1999). Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98, 147-157.
7. Casazza, A., Fu, X., Johansson, I., Capparuccia, L., Andersson, F., Giustacchini, A., Squadrito, M. L., Venneri, M. A., Mazzone, M., Larsson, E. et al. (2011). Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. Arterioscler. Thromb. Vasc. Biol. 31, 741-749.
8. Catalano, A., Caprari, P., Moretti, S., Faronato, M., Tamagnone, L. and Procopio, A. (2006). Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function. Blood 107, 3321-3329.
9. Chakraborty, G., Kumar, S., Mishra, R., Patil, T. V. and Kundu, G. C. (2012). Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model. PLoS ONE 7, e33633.
10. Crosby, C. V., Fleming, P. A., Argraves, W. S., Corada, M., Zanetta, L., Dejana, E. and Drake, C. J. (2005). VE-cadherin is not required for the formation of nascent blood vessels but acts to prevent their disassembly. Blood 105, 2771-2776.
11. Dejana, E. (2004). Endothelial cell-cell junctions: happy together. Nat. Rev. Mol. Cell Biol. 5, 261-270.
12. Dwyer, J., Le Guelte, A., Galan Moya, E. M., Sumbal, M., Carlotti, A., Douguet, L., Gutkind, J. S., Grange, P. A., Dupin, N. and Gavard, J. (2011). Remodeling of VE-cadherin junctions by the human herpes virus 8 G-protein coupled receptor. Oncogene 30, 190-200.
13. Edgell, C. J., McDonald, C. C. and Graham, J. B. (1983). Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc. Natl. Acad. Sci. USA 80, 3734-3737.
14. Eliceiri, B. P., Paul, R., Schwartzberg, P. L., Hood, J. D., Leng, J. and Cheresh, D. A. (1999). Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4, 915-924.
15. Galan-Moya, E. M., Le Guelte, A., Lima Fernandes, E., Thirant, C., Dwyer, J., Bidere, N., Couraud, P. O., Scott, M. G., Junier, M. P., Chneiweiss, H. et al. (2011). Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway. EMBO Rep. 12, 470-476.
16. Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., Fiocco, R., Foroni, C., Dimeco, F. and Vescovi, A. (2004). Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 7011-7021.
17. Gaur, P., Bielenberg, D. R., Samuel, S., Bose, D., Zhou, Y., Gray, M. J., Dallas, N. A., Fan, F., Xia, L., Lu, J. et al. (2009). Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clin. Cancer Res. 15, 6763-6770.
18. Gavard, J. (2009). Breaking the VE-cadherin bonds. FEBS Lett. 583, 1-6.
19. Gavard, J. and Gutkind, J. S. (2006). VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat. Cell Biol. 8, 1223-1234.
20. Gu, C., Rodriguez, E. R., Reimert, D. V., Shu, T., Fritzsch, B., Richards, L. J., Kolodkin, A. L. and Ginty, D. D. (2003). Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev. Cell 5, 45-57.
21. Guttmann-Raviv, N., Shraga-Heled, N., Varshavsky, A., Guimaraes-Sternberg, C., Kessler, O. and Neufeld, G. (2007). Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J. Biol. Chem. 282, 26294-26305.
22. Joyal, J. S., Sitaras, N., Binet, F., Rivera, J. C., Stahl, A., Zaniolo, K., Shao, Z., Polosa, A., Zhu, T., Hamel, D. et al. (2011). Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A. Blood 117, 6024-6035.
23. Le Guelte, A., Dwyer, J. and Gavard, J. (2011). Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer. Biol. Cell 103, 593-605.
24. Lin, M. I., Yu, J., Murata, T. and Sessa, W. C. (2007). Caveolin-1-deficient mice have increased tumor microvascular permeability, angiogenesis, and growth. Cancer Res. 67, 2849-2856.
25. Maione, F., Molla, F., Meda, C., Latini, R., Zentilin, L., Giacca, M., Seano, G., Serini, G., Bussolino, F. and Giraudo, E. (2009). Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin. Invest. 119, 3356-3372.
26. Maione, F., Capano, S., Regano, D., Zentilin, L., Giacca, M., Casanovas, O., Bussolino, F., Serini, G. and Giraudo, E. (2012). Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J. Clin. Invest. 122, 1832-1848.
27. Murakami, M., Nguyen, L. T., Zhuang, Z. W., Moodie, K. L., Carmeliet, P., Stan, R. V. and Simons, M. (2008). The FGF system has a key role in regulating vascular integrity. J. Clin. Invest. 118, 3355-3366.
28. Nawroth, R., Poell, G., Ranft, A., Kloep, S., Samulowitz, U., Fachinger, G., Golding, M., Shima, D. T., Deutsch, U. and Vestweber, D. (2002). VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts. EMBO J. 21, 4885-4895.
29. Nottebaum, A. F., Cagna, G., Winderlich, M., Gamp, A. C., Linnepe, R., Polaschegg, C., Filippova, K., Lyck, R., Engelhardt, B., Kamenyeva, O. et al. (2008). VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF. J. Exp. Med. 205, 2929-2945.
30. Nunbhakdi-Craig, V., Machleidt, T., Ogris, E., Bellotto, D., White, C. L., 3rd and Sontag, E. (2002). Protein phosphatase 2A associates with and regulates atypical PKC and the epithelial tight junction complex. J. Cell Biol. 158, 967-978.
31. Patru, C., Romao, L., Varlet, P., Coulombel, L., Raponi, E., Cadusseau, J., Renault-Mihara, F., Thirant, C., Leonard, N., Berhneim, A. et al. (2010). CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of longterm cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer 10, 66.
32. Piaton, G., Aigrot, M. S., Williams, A., Moyon, S., Tepavcevic, V., Moutkine, I., Gras, J., Matho, K. S., Schmitt, A., Soellner, H. et al. (2011). Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. Brain 134, 1156-1167.
33. Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., Maira, G., Parati, E. A., Stassi, G., Larocca, L. M. et al. (2010). Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468, 824-828.
34. Samanta, A. K., Chakraborty, S. N., Wang, Y., Kantarjian, H., Sun, X., Hood, J., Perrotti, D. and Arlinghaus, R. B. (2009). Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 28, 1669-1681.
35. Schulte, D., Küppers, V., Dartsch, N., Broermann, A., Li, H., Zarbock, A., Kamenyeva, O., Kiefer, F., Khandoga, A., Massberg, S. et al. (2011). Stabilizing the VE-cadherin-catenin complex blocks leukocyte extravasation and vascular permeability. EMBO J. 30, 4157-4170.
36. Serini, G., Valdembri, D., Zanivan, S., Morterra, G., Burkhardt, C., Caccavari, F., Zammataro, L., Primo, L., Tamagnone, L., Logan, M. et al. (2003). Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424, 391-397.
37. Serini, G., Maione, F., Giraudo, E. and Bussolino, F. (2009). Semaphorins and tumor angiogenesis. Angiogenesis 12, 187-193.
38. Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D. and Dirks, P. B. (2004). Identification of human brain tumour initiating cells. Nature 432, 396-401.
39. Sontag, E. (2001). Protein phosphatase 2A: the Trojan Horse of cellular signaling. Cell. Signal. 13, 7-16.
40. Sorensen, A. G., Batchelor, T. T., Zhang, W. T., Chen, P. J., Yeo, P., Wang, M., Jennings, D., Wen, P. Y., Lahdenranta, J., Ancukiewicz, M. et al. (2009). A "vascular normalization index"as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 69, 5296-5300.
41. Stockton, R. A., Schaefer, E. and Schwartz, M. A. (2004). p21-activated kinase regulates endothelial permeability through modulation of contractility. J. Biol. Chem. 279, 46621-46630.
42. Suzuki, K. and Takahashi, K. (2006). Induction of E-cadherin endocytosis by loss of protein phosphatase 2A expression in human breast cancers. Biochem. Biophys. Res. Commun. 349, 255-260.
43. Switzer, C. H., Cheng, R. Y., Vitek, T. M., Christensen, D. J., Wink, D. A. and Vitek, M. P. (2011). Targeting SET/I(2)PP2A oncoprotein functions as a multipathway strategy for cancer therapy. Oncogene 30, 2504-2513.
44. Taddei, A., Giampietro, C., Conti, A., Orsenigo, F., Breviario, F., Pirazzoli, V., Potente, M., Daly, C., Dimmeler, S. and Dejana, E. (2008). Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat. Cell Biol. 10, 923-934.
45. ten Klooster, J. P., Leeuwen, I., Scheres, N., Anthony, E. C. and Hordijk, P. L. (2007). Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET. EMBO J. 26, 336-345.
46. Thirant, C., Galan-Moya, E. M., Dubois, L. G., Pinte, S., Chafey, P., Broussard, C., Varlet, P., Devaux, B., Soncin, F., Gavard, J. et al. (2012). Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor. Stem Cells 30, 845-853.
47. Vestweber, D., Winderlich, M., Cagna, G. and Nottebaum, A. F. (2009). Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol. 19, 8-15.
48. Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K. E., Geber, A., Fligelman, B., Leversha, M., Brennan, C. and Tabar, V. (2010). Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468, 829-833.
49. Weis, S., Shintani, S., Weber, A., Kirchmair, R., Wood, M., Cravens, A., McSharry, H., Iwakura, A., Yoon, Y. S., Himes, N. et al. (2004). Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J. Clin. Invest. 113, 885-894.
50. Weksler, B. B., Subileau, E. A., Perrière, N., Charneau, P., Holloway, K., Leveque, M., Tricoire-Leignel, H., Nicotra, A., Bourdoulous, S., Turowski, P. et al. (2005). Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 19, 1872-1874.
51. Westermarck, J. and Hahn, W. C. (2008). Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol. Med. 14, 152-160.
52. Yokoyama, N. and Miller, W. T. (2001). Protein phosphatase 2A interacts with the Src kinase substrate p130(CAS). Oncogene 20, 6057-6065.
53. Yuan, X., Curtin, J., Xiong, Y., Liu, G., Waschsmann-Hogiu, S., Farkas, D. L., Black, K. L. and Yu, J. S. (2004). Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23, 9392-9400.